‘Bausch Health Hires Advisers Amid Patent Loss, Spinoff Controversy’ -Wall Street Journal
https://www.wsj.com/articles/bausch-health-hires-advisers-amid-patent-loss-spinoff-controversy-11661201254
Bausch Health Continuing Process Toward Separating Bausch + Lomb
Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") has transferred common shares in an amount equal to approximately 38.6% of the issued and outstanding shares of Bausch + Lomb
Expert Ratings for Bausch & Lomb
Bausch & Lomb (NYSE:BLCO) has observed the following analyst ratings within the last quarter:
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Traders Circulate July 14 CreditSights Report ‘Bausch Health faces a critically important patent ruling for Xifaxan in early August.;’ Traders Circulate Speculation Of Legal Issue With Patent
https://twitter.com/creditsights/status/1547599155970732033
‘Well-Established’ Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst
RBC Capital markets initiated coverage on Bausch + Lomb Corp (NYSE:BLCO) with an Outperform rating and a $22 price target. The analysts see…
RBC Capital Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $22
RBC Capital analyst Douglas Miehm initiates coverage on Bausch & Lomb (NYSE:BLCO) with a Outperform rating and announces Price Target of $22.
Bausch + Lomb Enrolls First Patient In LASIK Clinical Trial Evaluating Use Of Technolas TENEO™ Excimer Laser For Vision Correction Surgery for Hyperopia with Astigmatism
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient